Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 387 across all filing types
Latest filing 2021-03-05 Board/Management Inform…
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing a new partnership and management appointments at Psyence Group Inc. It discusses a Service Level Agreement with Base Pair Health and the strengthening of the management team with new executive appointments. There is no financial data, no mention of quarterly or annual results, no regulatory filings, no voting results, no audit information, and no mention of any report being attached or published. The content focuses on corporate developments and management changes. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains substantive information about management changes, not just a brief announcement or a report publication notice.
2021-03-05 English
News release - English.pdf
Regulatory Filings
2021-03-04 English
Financial statements of RTO acquirer.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for the three months ended December 31, 2020, and includes detailed unaudited financial statements such as the statement of financial position, net loss and comprehensive loss, changes in shareholders' equity, and cash flows. It also contains notes explaining the basis of presentation, accounting policies, and management responsibility. The document explicitly states it is prepared in accordance with IAS 34 - Interim Financial Reporting, which is the standard for interim (quarterly or half-year) financial reports. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2020
2021-03-01 English
Notice.pdf
Regulatory Filings Classification · 95% confidence The document is a Notice of Change in Corporate Structure pursuant to a specific regulatory instrument (National Instrument 51-102). It details a reverse takeover transaction, share consolidation, name change, and changes in financial year-end. It references various filings and financial statements to be filed subsequently but does not itself contain financial statements or detailed financial data. The document is primarily an announcement of a corporate transaction and structural changes rather than a full financial report or detailed management discussion. It also references other filings and documents but does not present them. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-02-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaboration agreement between Psyence Group and MycoMeditations to conduct an observational study on psilocybin therapy. It discusses the study's design, expected outcomes, and future research plans. There are no financial statements, regulatory filings, or detailed financial data. The content is primarily a corporate announcement about a research collaboration, not a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a corporate development related to research collaboration, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-02-10 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing that Psyence Group's CEO will be presenting at a specific investor conference. It includes details about the conference, the company's business focus, and a webcast link. There is no financial data, no report attached or referenced as being published, and no regulatory filing or voting results. This is an investor presentation announcement rather than the presentation itself or a financial report. Given the nature of the content, the most appropriate classification is Investor Presentation (IP). However, since this is an announcement of a presentation event rather than the presentation document itself, it is closest to an Investor Presentation category rather than a report publication or regulatory filing. Confidence is high due to clear context and content.
2021-02-10 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.